Does the Piperacillin Minimum Inhibitory Concentration for Pseudomonas aeruginosa Influence Clinical Outcomes of Children With Pseudomonal Bacteremia?

Background. The Clinical and Laboratory Standards Institute (CLSI) recently elected to adjust the previous piperacillin susceptibility breakpoint of ≤64 µg/mL against Pseudomonas aeruginosa to ≤16 µg/mL, based largely on pharmacokinetic–pharmacodynamic (PK–PD) modeling studies. Data on whether PK–PD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tamma, Pranita D., Turnbull, Alison E., Milstone, Aaron M., Hsu, Alice J., Carroll, Karen C., Cosgrove, Sara E.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Articles and Commentaries
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657512/
https://ncbi.nlm.nih.gov/pubmed/22696019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis545
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars